JP2002542196A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002542196A5 JP2002542196A5 JP2000611917A JP2000611917A JP2002542196A5 JP 2002542196 A5 JP2002542196 A5 JP 2002542196A5 JP 2000611917 A JP2000611917 A JP 2000611917A JP 2000611917 A JP2000611917 A JP 2000611917A JP 2002542196 A5 JP2002542196 A5 JP 2002542196A5
- Authority
- JP
- Japan
- Prior art keywords
- sgk
- inhibitor
- human cell
- sodium channel
- cell volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 description 10
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 210000005260 human cell Anatomy 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- LLEJIEBFSOEYIV-UHFFFAOYSA-N chelerythrine Chemical compound C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 LLEJIEBFSOEYIV-UHFFFAOYSA-N 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 102000003837 Epithelial Sodium Channels Human genes 0.000 description 6
- 108090000140 Epithelial Sodium Channels Proteins 0.000 description 6
- 101000640897 Squalus acanthias Solute carrier family 12 member 2 Proteins 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 108020003264 Cotransporters Proteins 0.000 description 5
- 102000034534 Cotransporters Human genes 0.000 description 5
- 206010006458 Bronchitis chronic Diseases 0.000 description 4
- 201000003883 Cystic fibrosis Diseases 0.000 description 4
- RATMHCJTVBHJSU-UHFFFAOYSA-N Dihydrochelerythrine Natural products C1=C2OCOC2=CC2=C(N(C)C(O)C=3C4=CC=C(C=3OC)OC)C4=CC=C21 RATMHCJTVBHJSU-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010033645 Pancreatitis Diseases 0.000 description 4
- 206010006451 bronchitis Diseases 0.000 description 4
- 208000007451 chronic bronchitis Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 208000034189 Sclerosis Diseases 0.000 description 3
- 108010052164 Sodium Channels Proteins 0.000 description 3
- 102000018674 Sodium Channels Human genes 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 101100163901 Rattus norvegicus Asic2 gene Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 102100022094 Acid-sensing ion channel 2 Human genes 0.000 description 1
- 101710099902 Acid-sensing ion channel 2 Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000030632 cutaneous sclerosis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19917990.5 | 1999-04-20 | ||
| DE19917990A DE19917990A1 (de) | 1999-04-20 | 1999-04-20 | Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk |
| PCT/EP2000/003578 WO2000062781A1 (de) | 1999-04-20 | 2000-04-19 | Arzneimittel enthaltend hemmstoffe der zellvolumenregulierten humanen kinase h-sgk |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002542196A JP2002542196A (ja) | 2002-12-10 |
| JP2002542196A5 true JP2002542196A5 (https=) | 2007-06-14 |
Family
ID=7905297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000611917A Pending JP2002542196A (ja) | 1999-04-20 | 2000-04-19 | 細胞容量調節ヒトキナーゼｈ−ｓｇｋのインヒビター含有医薬 |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1171131A1 (https=) |
| JP (1) | JP2002542196A (https=) |
| KR (1) | KR100718900B1 (https=) |
| CN (1) | CN1351496A (https=) |
| AU (1) | AU779941B2 (https=) |
| BR (1) | BR0009914A (https=) |
| CA (1) | CA2369078A1 (https=) |
| CZ (1) | CZ20013778A3 (https=) |
| DE (1) | DE19917990A1 (https=) |
| HU (1) | HUP0200819A3 (https=) |
| MX (1) | MXPA01010588A (https=) |
| NO (1) | NO20015054L (https=) |
| PL (1) | PL198427B1 (https=) |
| RU (1) | RU2288718C9 (https=) |
| SK (1) | SK14972001A3 (https=) |
| UA (1) | UA79066C2 (https=) |
| WO (1) | WO2000062781A1 (https=) |
| ZA (1) | ZA200108610B (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10042137A1 (de) * | 2000-08-28 | 2002-03-14 | Florian Lang | sgk2 und sgk3 als diagnostische und therapeutische Targets |
| DE10113876A1 (de) * | 2001-03-21 | 2002-09-26 | Eberhard Karls Uni Medizinisch | Quantitative diagnostische Analyse der Hypertonie |
| ATE439797T1 (de) * | 2001-04-27 | 2009-09-15 | Cold Spring Harbor Lab | Linderung der gedächtnisdefizite und gedächtniskomponenten von psychiatrischen funktionsstírungen durch veränderung der atypischen pkm-aktivität |
| DE10149393A1 (de) * | 2001-09-28 | 2003-04-24 | Florian Lang | sgk1 als diagnostisches und therapeutisches target |
| DE10225844A1 (de) * | 2002-06-04 | 2003-12-18 | Lang Florian | sgk und nedd als diagnostische und therapeutische targets |
| DE10305212A1 (de) * | 2003-02-07 | 2004-08-19 | Florian Prof. Dr.med. Lang | Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom |
| KR101032281B1 (ko) * | 2003-03-03 | 2011-05-06 | 플로리안 랑 | 진단 및 치료 표적으로서의 ｓｇｋ１ |
| WO2004084889A1 (en) * | 2003-03-28 | 2004-10-07 | Pfizer Inc. | Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons |
| DE10346913A1 (de) * | 2003-10-09 | 2005-05-04 | Merck Patent Gmbh | Acylhydrazonderivate |
| WO2005084702A1 (ja) * | 2004-03-02 | 2005-09-15 | Hokkaido Technology Licensing Office Co., Ltd. | 臓器線維症予防・治療剤 |
| RU2006135653A (ru) * | 2004-03-11 | 2008-04-20 | Мерк Патент ГмбХ (DE) | Способы, препятствующие фиброзу |
| KR20070015148A (ko) * | 2004-03-11 | 2007-02-01 | 메르크 파텐트 게엠베하 | 혈청 및 글루코코르티코이드 유도가능한 키나아제의조절제의 용도를 포함하는 신경정신학적 장애를 치료하기위한 글루탐산 수용체의 조절 방법 |
| US20090136920A1 (en) * | 2004-04-30 | 2009-05-28 | Stefan Golz | Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1) |
| WO2005118832A2 (en) * | 2004-06-01 | 2005-12-15 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase-like protein (sgkl) |
| DE102004030987A1 (de) * | 2004-06-26 | 2006-01-12 | Merck Patent Gmbh | Ortho-substituierte (3-Hydroxyphenyl)-essigsäure-benzyliden-hydrazide |
| MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| DE102005001053A1 (de) * | 2005-01-07 | 2006-07-20 | Merck Patent Gmbh | Quadratsäurederivate |
| DE102005015255A1 (de) | 2005-04-04 | 2006-10-05 | Merck Patent Gmbh | Acylhydrazide |
| DE102005035742A1 (de) * | 2005-07-29 | 2007-02-01 | Merck Patent Gmbh | Quadratsäurederivate II |
| DE102005039541A1 (de) * | 2005-08-22 | 2007-03-22 | Merck Patent Gmbh | 3-Oxo-indazol-quadratsäurederivate |
| DE102007002717A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
| DE102007022565A1 (de) | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
| EP2014651A1 (en) * | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Compounds and methods for modulating Rho GTPases |
| DE102008010361A1 (de) | 2008-02-18 | 2009-08-20 | Merck Patent Gmbh | sgk1-Inhibitoren zur Prophylaxe und/oder Therapie von viralen Erkrankungen und/oder Karzinomen |
| DE102008010362A1 (de) * | 2008-02-18 | 2009-08-20 | Florian Prof. Dr. Lang | Sgk1 als therapeutisches und diagnostisches Target für virale Erkrankungen |
| DE102008010363A1 (de) | 2008-02-18 | 2009-08-20 | Lang, Florian, Prof. Dr.med. | Sgk1 als therapeutisches und diagnostisches Target für karzinomatöse Erkrankungen |
| DE102008029072A1 (de) * | 2008-06-10 | 2009-12-17 | Lang, Florian, Prof. Dr.med. | Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen |
| DE102008038220A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Oxadiazolderivate |
| DE102008038222A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Indazol-5-carbonsäurehydrazid-derivate |
| DE102008038221A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-Azaindolderivate |
| DE102008059133A1 (de) | 2008-11-26 | 2010-05-27 | Merck Patent Gmbh | Difluorphenyl-diacylhydrazid-derivate |
| US8802099B2 (en) | 2010-11-10 | 2014-08-12 | National Jewish Health | Methods to treat allergic conditions |
| CN107875153A (zh) * | 2017-11-16 | 2018-04-06 | 上海壹志医药科技有限公司 | 去甲白屈菜红碱的药物用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5373501A (en) * | 1976-12-11 | 1978-06-30 | Kitasato Inst | Novel antibiotics amm2282 and process for preparing same |
| US5242397A (en) * | 1989-06-20 | 1993-09-07 | Cedars-Sinai Medical Center | Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty |
| US5137912A (en) * | 1991-01-28 | 1992-08-11 | National Science Council Of Republic Of China | Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug |
| DE4217964A1 (de) * | 1992-05-30 | 1993-12-02 | Goedecke Ag | Indolocarbazol-Imide und deren Verwendung |
| GB9325395D0 (en) * | 1993-12-11 | 1994-02-16 | Ciba Geigy Ag | Compositions |
| US5874464A (en) * | 1995-01-13 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Conformationally constrained diacylglycerol analogues |
| WO1997007081A2 (en) * | 1995-08-11 | 1997-02-27 | Yale University | Glycosylated indolocarbazole synthesis |
| IL126873A (en) * | 1996-05-30 | 2005-09-25 | Aventis Pharma Inc | Alkyloxyamino substituted fluorenones and their use as protein kinase c inhibitors |
| EP0887081B1 (en) * | 1997-06-27 | 2003-04-23 | Smithkline Beecham Corporation | Human serum glucocorticoid regulated kinase, a target for chronic renal disease and diabetic nephropathy |
| EP0889127A1 (en) * | 1997-07-01 | 1999-01-07 | Smithkline Beecham Corporation | Serine/threonine protein kinase (H-SGK2) |
| CO4940430A1 (es) * | 1997-07-07 | 2000-07-24 | Novartis Ag | Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales |
-
1999
- 1999-04-20 DE DE19917990A patent/DE19917990A1/de not_active Ceased
-
2000
- 2000-04-19 RU RU2001131351/15A patent/RU2288718C9/ru not_active IP Right Cessation
- 2000-04-19 WO PCT/EP2000/003578 patent/WO2000062781A1/de not_active Ceased
- 2000-04-19 SK SK1497-2001A patent/SK14972001A3/sk unknown
- 2000-04-19 MX MXPA01010588A patent/MXPA01010588A/es not_active Application Discontinuation
- 2000-04-19 HU HU0200819A patent/HUP0200819A3/hu unknown
- 2000-04-19 CZ CZ20013778A patent/CZ20013778A3/cs unknown
- 2000-04-19 CN CN00807959A patent/CN1351496A/zh active Pending
- 2000-04-19 BR BR0009914-7A patent/BR0009914A/pt not_active Application Discontinuation
- 2000-04-19 JP JP2000611917A patent/JP2002542196A/ja active Pending
- 2000-04-19 PL PL352547A patent/PL198427B1/pl unknown
- 2000-04-19 EP EP00922655A patent/EP1171131A1/de not_active Withdrawn
- 2000-04-19 KR KR1020017013336A patent/KR100718900B1/ko not_active Expired - Fee Related
- 2000-04-19 CA CA002369078A patent/CA2369078A1/en not_active Abandoned
- 2000-04-19 AU AU42972/00A patent/AU779941B2/en not_active Ceased
- 2000-04-19 UA UA2001117896A patent/UA79066C2/uk unknown
-
2001
- 2001-10-17 NO NO20015054A patent/NO20015054L/no not_active Application Discontinuation
- 2001-10-19 ZA ZA200108610A patent/ZA200108610B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002542196A5 (https=) | ||
| JP6974120B2 (ja) | ヒストンデアセチラーゼ阻害剤 | |
| US20210251848A1 (en) | Treatment of bleeding by non-invasive stimulation | |
| Barr et al. | Withdrawal following repeated exposure to d-amphetamine decreases responding for a sucrose solution as measured by a progressive ratio schedule of reinforcement | |
| RU2001131351A (ru) | Лекарственные средства, содержащие ингибиторы человеческой н-sgk киназы, контролирующие клеточный объем | |
| JP2003517437A5 (ja) | 処方した人の脳シチジンレベルを上昇させる薬を調合するためのウリジンの使用方法及び同薬として使用する組成物 | |
| TW200510349A (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | |
| JP2001523245A (ja) | 肥満を治療するためのｎｋ−１受容体拮抗薬およびｓｓｒｉの使用 | |
| JPH11507045A (ja) | 可逆性システインプロテアーゼ抑制剤 | |
| EP1372620A2 (en) | Methods for restoring cognitive function following systemic stress | |
| ES2385138T3 (es) | Modelo de roedor de enfermedad para dolor muscular crónico | |
| CY1115638T1 (el) | Θεραπεια ψευδαισθητικων φαινομενων | |
| US9629847B2 (en) | Compositions and methods for treating symptoms of inflammatory related conditions using a combination of an antihistamine and a stimulant | |
| JPWO2004060400A1 (ja) | 上皮成長因子受容体を分子標的とする抗精神病薬 | |
| Taylor et al. | Chronic fluoxetine microdialysis into the medullary raphe nuclei of the rat, but not systemic administration, increases the ventilatory response to CO2 | |
| US9149474B2 (en) | Compositions and methods for treating symptoms of inflammatory related conditions using a combination of an antihistamine and a stimulant | |
| Domino et al. | Pharmacologic evidence for cholinergic mechanisms in neocortical and limbic activating systems | |
| Haji et al. | Distribution of μ receptors in the ventral respiratory group neurons; immunohistochemical and pharmacological studies in decerebrate cats | |
| KR20090083891A (ko) | Ｓ-니트로소티올 화합물 및 관련 유도체 | |
| DE602005002734D1 (de) | Derivate von genkwanin und sakuranetin, deren kosmetische und therapeutische verwendung, und verfahren zu deren herstellung | |
| JP2005523270A5 (https=) | ||
| IL194346A0 (en) | Peptide substance stimulating regeneration of central nervous system neurons, pharmaceutical composition on its base, and the method of its application | |
| JP2004535386A (ja) | 学習および記憶を増強させるためのカルボニックアンヒドラーゼ活性化剤 | |
| CN115175678B (zh) | 使用btk抑制剂及其组合治疗dlbcl的方法 | |
| Wilson et al. | Antinociceptive properties of tiletamine-zolazepam improved by addition of xylazine or butorphanol |